1601 Cloverfield Blvd., 100 South Tower
28 articles with Kite Pharma
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
2/22/2018Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
12/12/2017A look at some of the exciting data clinicians and investors got to feast on from ASH.
The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta.
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.
CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis.
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
BioLife Solutions today announced that its customer Kite Pharma has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.